The goal for this project is to develop a reliable, accessible, and actionable test to identify dogs at risk for hemangiosarcoma during the earliest stages of disease and to use a strategic, rationally designed approach to prevent its occurrence in these high-risk dogs before it becomes clinically detrimental and life-threatening. The study has two objectives. The first is to determine the most reasonable duration of an SOS test result. In other words, how long can a low-risk SOS test result be trusted and how much time might elapse between a high-risk SOS test result and the development of hemangiosarcoma. The second aim is to continue periodic testing for dogs previously enrolled in the Shine On study whose test result would have placed them in a high-risk category for development of hemangiosarcoma, and to provide eBAT as a strategy for prevention in 12 of these dogs. Continue reading “Research Update CHF 02806-MOU MY1: Strategic Prevention of Canine Hemangiosarcoma: Lifetime Follow-Up”
Research Update CHF 02519 EY3: Prevalence of Bartonella spp. Infection in Dogs with Cardiac and Splenic Hemangiosarcomas Within and Between Geographic Locations
We are on track to accomplish all of our aims for this study. We were able to obtain the initial set of samples on April 26, 2018 so we had a short delay in starting this study. We have now completed all Year I study aims, with the exception of immunohistochemistry and FISH localization of Bartonella organisms within various cell types. Continue reading “Research Update CHF 02519 EY3: Prevalence of Bartonella spp. Infection in Dogs with Cardiac and Splenic Hemangiosarcomas Within and Between Geographic Locations”
Research Update CHF 02534 MY 2 Update: Clinical Trial for Evaluation of Propranolol and Doxorubicin in the Treatment of Canine Hemangiosarcoma
During the first 18 months of the trial, we have made progress toward our objectives. The project goals have not been modified.
Our overall objective is to determine a clinically optimal dose and estimate the efficacy of propranolol in dogs with hemangiosarcoma when given as an adjunct to chemotherapy. Continue reading “Research Update CHF 02534 MY 2 Update: Clinical Trial for Evaluation of Propranolol and Doxorubicin in the Treatment of Canine Hemangiosarcoma”
Research Update CHF 02528 MY2: Developing a Next Generation Sequencing Diagnostic Platform for Tick-Borne Diseases
Despite the wide availability of tick-borne disease panels at laboratories in the USA and abroad, most results from sick dogs are negative, which frustrates veterinarians and dog owners trying to reach a definitive diagnosis. Continue reading “Research Update CHF 02528 MY2: Developing a Next Generation Sequencing Diagnostic Platform for Tick-Borne Diseases”
Research Update Mid-year 3 CHF 02519: Prevalence of Bartonella spp. Infection in Dogs with Cardiac and Splenic Hemangiosarcomas Within and Between Geographic Locations
We are on track to accomplish all of our aims for this study. We were able to obtain the initial set of samples on April 26, 2018 so we had a short delay in starting this study. We have now completed all Year I study aims, with the exception of immunohistochemistry and FISH localization of Bartonella organisms within various cell types. An unanticipated complication arose that the mouse monoclonal antibody was no longer being made commercially. B. henselae specific FISH probes have been designed and validation of FISH probes are in-progress. IHC is also in- progress. All qPCR and ddPCR have been completed at this time and samples are waiting for FISH and IHC analysis.
Research Update End-year 1 CHF 02534: Clinical Trial for Evaluation of Propranolol and Doxorubicin in the Treatment of Canine Hemangiosarcoma
During the first year that the project has been active, we have made progress toward our objectives. The project goals have not been modified.
Our overall objective is to determine a clinically optimal dose and estimate the efficacy of propranolol in dogs with hemangiosarcoma when given as an adjunct to chemotherapy.
Lifetime Follow-Up of Canine Hemangiosarcoma
PARKER FORD, PA, July 13, 2020 09:00 ET — The Portuguese Water Dog Foundation is pleased to support the continuation phase of the Shine On project with the Golden Retriever Foundation, the American Boxer Charitable Foundation and the AKC Canine Health Foundation.
In this continuation phase of the Shine On project, the group of dogs that were originally enrolled in the study and received the Shine On Suspicion (SOS) Test will be followed for their lifetimes to identify any diagnosis of cancer or another chronic disease, the cause of death, and date of death.
Continue reading “Lifetime Follow-Up of Canine Hemangiosarcoma”
Research Update End-year 2 CHF 02519: Prevalence of Bartonella spp. Infection in Dogs with Cardiac and Splenic Hemangiosarcomas Within and Between Geographic Locations
Hemangiosarcoma (HSA) accounts for the majority of canine malignant splenic tumors and occurs in many large dog breeds, including mixed breeds. A less common site of HSA localization is the heart (cardiac HSA). Risk factors for both cardiac and splenic HSA remain unclear, confounding development of preventative strategies. The investigators recently reported a high prevalence of species of the bacterial genus Bartonella in dogs with HSA from North Carolina, suggesting a potential role in the initiation and/or progression of this cancer.
Research Update Mid-Year 1 CHF 02534: Clinical Trial for Evaluation of Propranolol and Doxorubicin in the Treatment of Canine Hemangiosarcoma
Update on clinical trial for hemangiosarcoma treatment from Dr. Dickerson.
Research Update Mid-Year-2 for CHF-02519: Prevelance of Bartonella Infection in Dogs with Cardiac and Splenic Hemangiosarcomas
Research update from Dr. Breitschwerdt looking at the potential role of the Tick-Borne bacterial infection, bartonella in the initiation and/or progression of hemangiosarcoma.
